Severe peripheral artery disease (PAD) is the predominant cause of ischemic ulcerations involving the lower extremities. PAD-associated ulcerations are typically distally located involving the feet, toes, and sometimes the calves. In contradistinction, atypical ischemic ulcerations of the lower extremity are often nonatherosclerotic in etiology, involve the proximal leg (thigh/buttocks), can evolve despite palpable distal pulses, and may coexist with other cutaneous aberrations (e.g. macules, purpura, nodules, and livedo reticularis). A differential diagnosis of atypical ischemic ulcerations involving the legs is presented.
Introduction
Ischemic ulcerations of the lower extremity are usually secondary to severe atherosclerotic peripheral artery disease (PAD). PAD-associated ulcerations are classically located on the toes, metatarsal heads and calcanei. Rarely the calves can ulcerate as well. Ischemic ulcerations are usually markedly painful and coexistent ischemic rest pain within the foot and toes is often described. The ulcer base is characteristically dry, and the color is pale, grey, or black. The distal pedal arteries (dorsalis pedis and posterior tibial) cannot be palpated. Supportive non-invasive studies include an absolute ankle systolic pressure less than 50 mmHg and a toe systolic pressure of less than 30 mmHg. 1 When the arteries are incompressible, a pulsed volume recording or photoplethysmographic waveform of < 5 mm amplitude corroborates critical ischemia. 2, 3 Affected patients typically have multilevel PAD, including significant tibioperoneal involvement.
In contrast to PAD-associated ischemic ulcers, atypical ischemic ulcerations of the lower extremity can arise from a variety of non-atherosclerotic disorders or from non-occlusive atherosclerotic disease. Like PAD-associated ulcerations, a painful pale or necrotic ulcer base exists. However, the loca-tion of these ulcerations is often dissimilar. As opposed to the classic distally oriented PAD leg ulcerations, atypical ischemic lower extremity ulcerations can involve the more proximal portions of the leg, including the thighs and buttocks. Additionally, the abdominal wall and breasts can be ulcerated. Unlike PAD ulcerations, atypical ischemic ulcerations can evolve in the absence of significant large artery occlusive disease and thus the distal pulses are often palpable. Additionally, atypical ischemic leg ulcerations may occur with other cutaneous abnormalities such as erythematous macules, purpura, petechiae, hemorrhagic bullae, nodules, and livedo reticularis. A differential diagnosis of these unusual ischemic ulcerations is listed in Table 1 .
Differential diagnosis
Antiphospholipid antibody syndrome In up to 40% of patients with the antiphospholipid antibody syndrome (APAS), dermatologic abnormalities can be the primary or presenting manifestation. 4, 5 Although livedo racemosa is the most Table 1 Atypical lower extremity ischemic ulcerations: differential diagnosis common cutaneous aberration, painful ischemic leg ulcerations of varying sizes can occur ( Figures 1A  and B ). A devastating, widespread, full-thickness, cutaneous necrosis involving not only the legs, but the arms, flanks and breasts has also been described. 6, 7 Coexistent cutaneous findings may include purpura, ecchymosis, subcutaneous nodules, splinter hemorrhages, fixed digital cyanosis (with or without ulcerations and/or gangrene), Raynaud's phenomenon, acrocyanosis, and superficial thrombophlebitis.
Clinical criteria for the APAS include arterial, venous, or small vessel thrombosis, in any organ or tissue. Various pregnancy-associated morbidities also fulfill the clinical criteria. Adjunctive laboratory criteria include IgG/IgM anticardiolipin antibodies at medium or high titer, lupus anticoagulant, and/or IgG/IgM anti-beta 2 glycoprotein I antibodies. Antibodies against phosphatidylserine may be present as well. These antibodies must be documented on two or more occasions, at least 6 weeks apart. 8 The characteristic pathologic finding is non-inflammatory thrombi occluding small and medium-sized dermal vessels.
Therapy for antiphospholipid antibody syndrome-associated ischemic ulcerations is not well defined, although when widespread cutaneous necrosis and/or digital gangrene are present, full dose anticoagulation appears prudent.
Calciphylaxis
Calciphylaxis is an uncommon necrotizing calcific ulcerative panniculitis that usually occurs in the setting of end stage renal disease. Calciphylaxis initially manifests as irregular livedo reticularis with subcutaneous nodules and plaques. Ultimately, markedly painful, large, necrotic ulcerations ensue ( Figure 2 ). The lower extremities are most commonly involved, although the upper extremities, abdomen, and buttocks can also be affected. Unusual sites of calciphylaxis include the penis, breasts, and neck. The distal pulses may be palpable in the absence of severe peripheral artery disease.
Elevated parathyroid hormone and hyperphosphatemia are the most common laboratory abnormalities. An elevated calcium × phosphorous product and hypercalcemia are less common findings. 9 Depressed levels of functional protein S, 10 protein C, 11 or both 12 have been reported. Plane film radiography sometimes reveals calcium within the walls of small, medium, and large arteries. Typical pathological findings include calcium deposition within dermal-sized blood vessels (arterioles and venules) and the subcutaneous tissues. Concurrent intimal hyperplasia, a lymphohistiocytic infiltrate, and/or fibrin microthrombi are other pathological abnormalities. A bone scan has been suggested as a substitute for biopsy. 13 Therapy is often ineffective yet controlling hypercalcemia, hyperphosphatemia, and hyperparathyroidism is recommended. Methods for controlling the calcium × phosphate product include eliminating vitamin D analogues, reducing calcium in the dialysis bath, decreasing dietary phosphate and calcium, and substituting sevelamer hydrochloride for calcium-based phosphate binders. 14 Although parathyroidectomy is often recommended, its value remains controversial. Other treatment recommen- dations with possible efficacy include hyperbaric oxygen, 15, 16 tissue plasminogen activator, 17 sodium thiosulfate, 18 and the biphosphonates. 19 Warfarin-induced skin necrosis Warfarin-induced skin necrosis is a rare complication of therapy with warfarin or other coumarin derivatives that usually occurs within 10 days of initiation of anticoagulation. This disorder is manifested by widespread, sometimes symmetrical, painful, full-thickness skin necrosis that preferentially involves fatty regions. In the lower extremities, the thighs and buttocks are most often affected ( Figures  3A and B ). Additional sites of involvement include the abdominal wall, breasts, back, and arms. Periulcerative skin findings include patchy erythema, petechiae, hemorrhagic vesicles/bullae, and ecchymosis.
Middle-aged obese females appear predisposed to warfarin skin necrosis. Inherited or acquired protein C 20 and/or S deficiency 21 is documented in some cases. Recent reports link warfarin-induced skin necrosis with heparin-induced thrombocytopenia. 22 Pathologic features include necrosis and erythrocyte extravasation within the dermis and subcutaneous tissues. Microthrombosis within the capillaries, post-capillary venules and small veins is characteristic yet the arterioles are spared. A significant inflammatory response is absent. Once gross tissue necrosis ensues, the biopsy becomes non-diagnostic.
No consensus exists regarding the best treatment approach to warfarin skin necrosis. Therapy is empiric, supportive and conservative with administration of vitamin K and fresh frozen plasma, discontinuation of warfarin, and temporary anticoagulation with unfractionated or low-molecular weight heparin. Surgery is often required with debridement, skin grafting, and even myocutaneous flaps. Warfarin is sometimes judiciously reinstituted, beginning with low doses (e.g. 0.5-1 mg/day) and overlapping heparin over several weeks. 23 Heparin skin necrosis A rare disorder, heparin skin necrosis typically develops within six to 12 days after exposure to heparin. Multiple painful erythematous nodules and plaques and/or hemorrhagic bullae initially develop that can progress to full-thickness necrotic ulcerations. The skin manifestations usually occur at the sites of heparin injections ( Figure 4A ); however, dermal involvement distant to injection sites can develop as well ( Figure 4B ). 24 The abdominal wall, thighs, and buttocks are typically affected. This disorder can occur with either unfractionated or lowmolecular weight heparin.
Heparin skin necrosis is frequently but not always a sign of heparin-induced thrombocytopenia (HIT) and thus can be a harbinger of arteriovenous thromboemboli. Other pathomechanisms such as local trauma or an allergic reaction may be causative. Absolute or relative thrombocytopenia is usually but not invariably found. IgG antibodies directed against a binary complex of platelet factor 4 and heparin are often present. Underlying protein S deficiency has rarely been identified. 25 Histologically, the findings resemble those of warfarin skin necrosis with microvascular thrombi in dermal venules and capillaries combined with a paucity of inflammatory cells.
Treatment is primarily empiric. If HIT is causative, immediate discontinuation of all unfractionated and low molecular weight heparin products is warranted followed by administration of a direct thrombin inhibitor or fondaparinux. In non-HIT-associated heparin skin necrosis, potential treatment options include aspirin, vitamin K antagonists, or changing the type of administered heparin. Surgical debridement and/or skin grafting may be required.
Vasculitis
Vasculitis presents with an array of clinical manifestations, many that involve the skin ( Figure 5 ). Specifically, ischemic-appearing leg ulcerations can occur with small and medium-sized vessel vasculitides. Additional vasculitic signs include palpable purpura, pustules, urticaria, livedo reticularis/racemosa, vesicles, subcutaneous nodules, petechiae, and distal gangrene. Subjective complaints such as fever, malaise, myalgias, and arthralgias may be present. Attendant multiorgan disease is another clue to the presence of vasculitis.
A definitive diagnosis requires a skin biopsy with direct immunofluorescence of a non-ulcerated site, livedo core, nodule, or active border of an ulcer. If a medium-sized vasculitis is suspected, the biopsy should extend to the subcutis. The pathological findings are specific to the size of vessel involvement (e.g. small vessel vasculitis is associated with venular fibrinoid necrosis and leukocytoclasia; mediumsized vasculitis produces a necrotizing arteritis). The biopsy results can be time dependent. For instance, in lesions that materialize in less than 12 hours or after 48 hours, a principally lymphocytic cellular infiltrate may be observed and classic leukocytoclasia can be missing. The scope of adjunctive laboratory assessment should be guided by the clinical presentation and size of the involved vessels.
Treatment of vasculitis should be individualized and is dependent on the specific vasculitic etiology. For isolated cutaneous small vessel vasculitis (CSVV), conservative therapy should be tried since the disease process is often self-limited. Dapsone and/or colchicine have been used in mild to moderate disease. 26, 27 When CSVV becomes refractory or is associated with marked systemic disease, more aggressive immunosuppressive and immune modulating medications can be tried. Medium-sized vasculitides such as polyarteritis nodosa (PAN) are treated with corticosteroids and cytotoxic agents.
Atheroembolic disease
Atheroemboli occur in the setting of PAD with embolization typically developing after a procedure such as vascular or cardiothoracic surgery or arteriography.
Although the 'blue toe syndrome' is a wellrecognized manifestation of atheroembolic disease, painful ischemic ulcerations involving the buttocks, thighs, and proximal calves can rarely develop as well ( Figure 6 ). Coexistent cutaneous signs may include livedo reticularis, subcutaneous nodules, petechiae, and purpura. Multisystem organ dysfunction may be present, which often includes renal failure and hypertension. Distal pedal pulses are frequently palpable.
Serologic abnormalities may include azotemia, elevated sedimentation rate, leukocytosis, eosinophilia, hypocomplementemia, thrombocytopenia, and anemia. Eosinophiluria, proteinuria, and leu-kocyturia can occur. While rarely necessary, a skin biopsy will characteristically display biconvex, needle-shaped cholesterol crystal clefts within the arteriolar lumen. Occasionally, a perivascular lymphocytic infiltrate and/or giant cell reaction is present.
Optimal therapy for atheroembolic-associated ischemic ulcerations is unclear. Appropriate pharmacologic management is speculative yet includes the use of statins, 28, 29 antiplatelet agents, iloprost, 30, 31 corticosteroids, 29, 32, 33 and cilostazol. 34 Although controversial, anticoagulation has been proposed to trigger atheroemboli; consequently, discontinuance of vitamin K antagonist therapy is often suggested. Surgical or endovascular procedures to exclude the atheroembolic nidus can be performed.
Brown recluse spider bite (Loxosceles genus)
Although a variety of spider bites have been purported to provoke dermonecrotic skin lesions, with the exception of the Loxosceles species, these associations are highly speculative. 35 The bite of the recluse spider can cause a dermonecrotic, ischemicappearing skin ulceration that most commonly involves the thigh. The bite is initially painless yet over the ensuing 2-6 hours, focal pain, pruritus, swelling, and erythema develop. Over the following hours and days, vesicles or blebs appear that may become hemorrhagic. As the lesion progresses, a central necrotic and cyanotic depression with peripheral erythema and sometimes ischemicappearing pallor evolves resembling a 'target' or 'bull's eye'. This constellation of colors gives the lesion a 'red, white, and blue' appearance. In severe envenomations, the necrotic region forms an eschar that ultimately sloughs, culminating in a deep ulceration that extends through the fat and to the muscular level.
Systemic or viscerocutaneous loxoscelism is manifested by arthralgias, fever, vomiting, and a widespread rash that can eventuate in disseminated intravascular coagulation, hemolysis, renal failure, hemoglobinuria, and myoglobinuria. Fortunately, systemic involvement is rare, occurring in between 0.7% and 1.8% of cases.
A variety of arachnid cytotoxins such as sphingomyelinase D appear responsible for skin necrosis, RBC lysis, and endothelial cell toxicity. The diagnosis of a recluse spider bite is not definitive unless the act is visualized and/or the causative arachnid is recovered. Loxosceles necrotic arachnidism only occurs within endemic areas such as the central southern states of North America, South America, Europe, and Asia.
Ulcer care consists of debridement of necrotic tissue and eschar, sometimes followed by split thickness skin grafting. Adjunctive pharmacotherapy Figure 6 While the 'blue toe syndrome' with livedo reticularis is a common presentation of atheroembolic disease, ischemic ulcerations involving the proximal portions of the leg can rarely occur as well. Multiple ischemic plaques, purpura, and ulcerations with peripheral erythema overlie the patellar region in a case of postcatheterization atheroembolic disease (photograph courtesy of Dr Robert Eberhardt).
(e.g. colchicine, dapsone, corticosteroids, antihistamines, non-steroidal anti-inflammatory drugs) or hyperbaric oxygen is controversial and not well substantiated by prospective trials. [36] [37] [38] Prophylactic and/or culture-directed antibiotics are often administered.
Discussion
PAD-associated leg ulcerations typically occur on the distal portions of the extremity such as the toes and along the pressure points of the feet and calcanei. The calves are sometimes involved as well. In contrast, ischemic ulcerations along a patient's thighs, buttocks, and/or abdominal wall should prompt a clinician to consider the differential diagnosis of atypical ischemic lower extremity ulcerations. Additionally, these unusual etiologies can also cause ulcerations along the distal as well as the proximal portions of the lower extremity. For example, a patient with atheroembolic disease, calciphylaxis, the antiphospholipid antibody syndrome, or vasculitis can potentially develop ischemic ulcerations extending from the toes to the buttocks.
Conventionally, a patient with PAD-associated ischemic ulcerations has severe multisegmental occlusive disease and non-palpable distal pulses. Consequently, the presence of ischemic ulcerations despite palpable distal pulses should generate an investigation for uncommon causes of ischemic limb ulcers. Yet the absence of palpable posterior tibial or dorsalis pedis pulses should not dissuade an examiner from considering atypical ischemic ulceration of the lower extremity. For instance, patients with calciphylaxis usually have end stage renal disease and thus are at risk for significant PAD with diminished or absent distal pulses. In the author's experience, the ulcerations of calciphylaxis are often incorrectly diagnosed as a manifestation of critical atherosclerotic arterial occlusive disease. Similarly, a patient with atheroemboli-induced ulcerations has underlying PAD and therefore may have decreased pulses.
When an individual presents with both lower extremity ischemic ulcerations and cutaneous abnormalities such as livedo, nodules, and/or purpura, the differential diagnosis of atypical ischemic lower extremity ulcerations should be recalled. Livedo reticularis is sometimes a harbinger of the painful ischemic ulcerations of calciphylaxis or atheroembolic disease and is a common manifestation of the antiphospholipid antibody syndrome and vasculitis as well. The combination of palpable purpura, livedo reticularis, and ischemic limb ulcerations suggests a causative vasculitis. Hemorrhagic bullae can occur with both warfarin and heparin skin necrosis in addition to spider bites.
The distinct clinical features of atypical lower extremity ischemic ulcerations are listed in Table 2 .
In contradistinction to the PAD patient, a battery of unusual serologic tests should be obtained when evaluating the patient with these variant necrotic limb ulcerations. For example, a heparin platelet antibody assay is warranted when the diagnosis of heparin skin necrosis is entertained. All patients with livedo reticularis and proximal leg ulcerations should undergo testing for the antiphospholipid antibody syndrome. Protein S and C levels may be helpful when considering the diagnosis of calciphylaxis, heparin skin necrosis, and warfarin skin necrosis (protein S and C levels should be assayed 2-3 weeks after warfarin discontinuance). A list of Table 3 Atypical lower extremity ischemic ulcerations: potential laboratory evaluation 1. Complete chemistry profile 2. Complete blood count with differential 3. Urinalysis; Hansen's stain for eosinophils; urinary sediment assessment 4. Antiphospholipid antibodies: anticardiolipin antibodies, lupus anticoagulant, anti-beta 2 glycoprotein-1 antibodies 5. Vasculitis profile: antinuclear antibody (ANA), rheumatoid factor, antineutrophilic cytoplasmic antibody (ANCA), hepatitis C antibody, hepatitis B antigen, complement (C3/C4), serum protein electrophoresis, cryoglobulins, sedimentation rate, C-reactive protein (other vasculitic serology may be required based on the clinical scenario). 6. Heparin-dependent IgG antiplatelet antibodies: platelet factor 4/ELISA; heparin-induced platelet activation assay (HIPA); serotonin release assay (SRA) 7. Parathyroid hormone (PTH); calculate the calcium × phosphate product 8. Protein S and C assay laboratory assays to consider in this unique ulcer population is listed in Table 3 .
Although a biopsy of the skin and subcutaneous tissue would not provide useful information in a patient with PAD-associated ulcerations, it can yield helpful and potentially diagnostic information for the patient with atypical ischemic ulcerations of the lower extremity. Characteristic biopsy findings are outlined in Table 4 .
Finally, therapy obviously differs for the atypical ischemic leg ulceration. Although revascularization is warranted for the typical PAD-associated ischemic leg ulceration, it is usually improper therapy for the atypical one. All ischemic ulcerations can potentially benefit from appropriate local care.
Conclusions
When evaluating a patient with lower extremity ischemic ulcerations, a diagnosis of peripheral artery disease is usually entertained. However, in the setting of attendant clinical findings inconsistent with those of stereotypical severe large artery occlusive disease, the seven causes of atypical ischemic lower extremity ulcerations should be recalled. Failing to expeditiously recognize these variant ulcer etiologies can potentially lead to costly and ineffective therapy, but more importantly, significant patient morbidity and mortality.
